Showing results (191-200 of 256) with videos related to
Sort By:
Pageof 26
Stroke|January 12, 2021
Advancing Stroke Recovery Through Improved Articulation of Nonpharmacological Intervention DoseKathryn S Hayward, Leonid Churilov, Emily J Dalton, et al.Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 14, 2026
A phase 2, randomized, multicenter, double-blind, placebo-controlled trial of S-adenosyl methionine in participants with mild cognitive impairment or dementia due to Alzheimer's diseaseSarah Holper, Kevin J Barnham, Leonid Churilov, et al.Journal of Alzheimer'S Disease Reports|December 18, 2025
Neurofilament light chain and voice acoustics in dementia diagnosis (NAVAIDD): Protocol for a cohort study assessing the real-world diagnostic utility of blood and digital biomarkers in clinical settingsSvetlana Ivanic, Adam P Vogel, Pratishtha Chatterjee, et al.Stroke|October 4, 2021
Timing and Dose of Upper Limb Motor Intervention After Stroke: A Systematic ReviewKathryn S Hayward, Sharon F Kramer, Emily J Dalton, et al.Nature Reviews. Neurology|November 13, 2023
Molecular biomarkers for vascular cognitive impairment and dementiaSatoshi Hosoki, Gurpreet K Hansra, Tharusha Jayasena, et al.International Journal of Stroke : Official Journal of the International Stroke Society|September 17, 2016
ASPREE-NEURO study protocol: A randomized controlled trial to determine the effect of low-dose aspirin on cerebral microbleeds, white matter hyperintensities, cognition, and stroke in the healthy elderlyStephanie A Ward, Parnesh Raniga, Nicholas J Ferris, et al.Brain : a Journal of Neurology|September 15, 2004
Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorderAmanPreet Badhwar, Samuel F Berkovic, John P Dowling, et al.Healthcare (Basel, Switzerland)|November 27, 2025
Movement-Based Mindfulness vs. Attention Control for Modifying Physiological Risk in Chronic Stroke: Evidence from a Feasibility TrialTharshanah Thayabaranathan, Marina Paul, Frederick R Walker, et al.Alzheimer'S & Dementia (New York, N. Y.)|May 16, 2022
A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementiaLucy Vivash, Charles B Malpas, Christian Meletis, et al.Journal of Alzheimer'S Disease : JAD|July 23, 2016
A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's DiseaseCharles B Malpas, Lucy Vivash, Sila Genc, et al.Pageof 26